Colorectal Cancer

New evidence-based guidance for bowel prep considers patient preference and history and updates timing of prep regimen, dietary restrictions, and follow-up recommendations.

The outsized burden continues among Black men, a group with prostate cancer incidence rates 67% higher than those of White men and mortality rates more than twice as high.

A family medicine specialist who works with cancer survivorship highlights findings of a study that illustrate how effective screening is and how treatment has changed.

World Cancer Day 2025 urges focus on the unique personal journey underlying every cancer diagnosis; individual recommendations for regular screening is where that can start.

Your daily dose of the clinical news you may have missed.

ASCO GI Cancers Symposium: The Freenome blood-based test identified nearly 80% of individuals who had colorectal cancer.

Annual colorectal cancer screening with FIT was the most cost-effective strategy among patients with low adherence, researchers reported.

Your daily dose of the clinical news you may have missed.

The USPSTF's revised CRC screening guidelines to include adults aged 45-49 years increased screening needs by about 23% without additional funding or resources for CHCs.

Your daily dose of the clinical news you may have missed.

A centralized mailed FIT outreach intervention significantly improved CRC screening in a diverse patient population, according to recent data

Find details on US colorectal cancer screening rates, dietary interventions for people with IBS, and research on the primary drivers of cost of IBD care.

William Grady, MD, talks about the latest research in colorectal cancer, including treatments targeting senescent cells that contribute to tumor formation.

William Grady, MD, highlights ongoing efforts to improve test sensitivity and developments of new blood-based tests for early detection of CRC.

William Grady, MD, coauthor of the ECLIPSE study, discusses the use of non-invasive cfDNA blood-based tests for CRC screening in older adults.

William Grady, MD, coauthor of the ECLIPSE trial, discusses how the Shield cfDNA blood-based test compares to traditional CRC screening methods.

William Grady, MD, highlights the convenience and compliance of blood-based tests compared to colonoscopy and stool-based tests for colorectal cancer screening.

Your daily dose of the clinical news you may have missed.

William Grady, MD, coauthor of the ECLIPSE clinical trial, discusses the study's rationale, methods, and key findings.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

ACG: Mortality associated with both early- and late-stage EO-CRC rose most significantly among young adults aged 20 to 44 years between 2000 and 2022, new research reveals.

ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.

More than half of US adults who had a colonoscopy in past 5 years said they wish they knew more information before their first procedure.

Nearly 40% of adults aged 45 to 50 years completed a fecal immunochemical test within 3 months, according to a large retrospective study.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Increases in CRC screening were higher in high socioeconomic status and metropolitan areas, according to a new large cohort study.

Cologuard Plus bests its previous iteration and demonstrates greater sensitivity and specificity for any CRC relative to fecal immunochemical tests.